Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study-Reference-Cited by-同舟云学术

Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study

Published:2019-03-21 Issue:1 Volume:30 Page:101-108
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Tanaka Yoshiya¹,Takeuchi Tsutomu²,Okada Masato³,Ishii Tomonori⁴,Nakajima Hiroshi⁵,Kawai Shinichi⁶,Nagashima Takao⁷,Hayashi Nobuya⁸,Wang Liangwei⁹,Tummala Raj⁹

Affiliation:

1. First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan;

2. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;

3. Division of Allergy & Rheumatology, St. Luke’s International Hospital, Tokyo, Japan;

4. Department of Rheumatology and Hematology, Tohoku University Hospital, Miyagi, Japan;

5. Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan;

6. Department of Inflammation & Pain Control Research, Toho University School of Medicine, Tokyo, Japan;

7. Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan;

8. Research and Development, AstraZeneca K.K., Osaka, Japan;

9. Global Medicine Division, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2019.1583833

Reference17 articles.

1. Pathogenesis of systemic lupus erythematosus

2. Monitoring systemic lupus erythematosus in standard clinical care

3. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus

4. The type I interferon system in the etiopathogenesis of autoimmune diseases

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers;BioDrugs;2023-12-27

2. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus;Expert Review of Clinical Immunology;2023-10-11

3. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab;Clinical Pharmacokinetics;2023-05

4. Anifrolumab in systemic lupus erythematosus;Drugs of Today;2023-02

5. Targeting type I interferons in systemic lupus erythematous;Frontiers in Pharmacology;2023-01-16